ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1899

sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia

Guilherme De Jesus1, Marcela Lacerda 1, Bruna Rodrigues 1, Flavia dos Santos 1, Adriana Nascimento 1, Luis Cristóvão Porto 1, Nilson Ramires de Jesús 1, Roger Levy 2 and Evandro Klumb 1, 1Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2GlaxoSmithKline, Upper Providence, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: differential diagnosis, Hypertension and systemic lupus erythematosus (SLE), Nephritis, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Pregnancy in patients with SLE is associated with significant morbidity and mortality. SLE activity during pregnancy, specifically nephritis, makes the differential diagnosis with preeclampsia (PE) troublesome in clinical practice. The use of angiogenic factors, like vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), and antiangiogenic factors, such as soluble Fms-like tyrosine kinase-1 (sFlt-1), has been proposed to help differentiate these two conditions, but there is no available data about these cytokines in this scenario. The objective of this study was to evaluate circulating levels of VEGF, PlGF and sFlt-1 in SLE pregnant women with inactive disease, active lupus nephritis and PE.

Methods: Patients with SLE (ACR criteria) with singleton pregnancies followed at a high risk prenatal care, without any other autoimmune disease, were included. They were divided according to disease activity using SLEPDAI (SLE Pregnancy Disease Activity Index), clinical and laboratory evaluation by a rheumatologist experienced in evaluating pregnant SLE patients and the occurrence of PE. Blood samples were collected at the third trimester of pregnancy, within 3 weeks of delivery, and frozen for subsequent blinded analysis by ELISA kits (PlGF – DRG Instruments, Marbug, Germany; sFlt-1 and VEGF – R&D systems, Minneapolis, United States).

Results: Seventy one women were included. Forty one patients had inactive SLE (Group 1, SLEPDAI < 4), 15 had active lupus nephritis (Group 2, SLEPDAI >4, including renal criteria) and 15 had PE (Group 3). Mean gestational age at blood collection was of 36.8, 33.7 and 34.5 weeks, respectively and delivery  at 38.7, 35.7 and 35.8 weeks, respectively; statistically significantly higher in patients with inactive SLE (Table 1). Mean levels of VEGF, PlGF and sFlt-1 of each group are reported on Table 2. Patients with SLE and PE had statistically significantly lower mean serum levels of PlGF than SLE patients without PE, while sFlt-1 was significantly higher in patients with PE compared to pregnant patients with inactive SLE or lupus nephritis. The sFlt-1/PlGF ratio was also significantly higher in patients of Group 3 (PE) compared to other patients with SLE (Groups 1 and 2). VEGF was higher in patients with SLE nephritis compared to inactive SLE and SLE with PE, while PlGF and sFlt-1 were similar when both groups without PE were compared.

Conclusion: In this study, pregnant SLE patients with PE had similar angiogenic and antiangiogenic profile of patients with PE without SLE – low PlGF and high sFlt-1, with high sFlt-1/PlGF ratio. This pattern differs from patients with inactive SLE or active lupus nephritis, the main differential diagnosis during gestation. Evaluation of angiogenic and antiangiogenic factors, specially PlGF and sFlt-1, can be a new tool to differentiate PE from lupus nephritis during pregnancy in clinical practice.

Table 1. Demographic and gestational results of patients with Inactive SLE, SLE nephritis and SLE with Preeclampsia.

Table 2. Mean values of VEGF, PlGF and sFlt-1 for patients with Inactive SLE, SLE nephritis and SLE with Preeclampsia.


Disclosure: G. De Jesus, None; M. Lacerda, None; B. Rodrigues, None; F. dos Santos, None; A. Nascimento, None; L. Porto, None; N. Ramires de Jesús, None; R. Levy, None; E. Klumb, None.

To cite this abstract in AMA style:

De Jesus G, Lacerda M, Rodrigues B, dos Santos F, Nascimento A, Porto L, Ramires de Jesús N, Levy R, Klumb E. sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/sflt-1-plgf-and-vegf-in-the-differential-diagnosis-between-active-sle-nephritis-during-pregnancy-and-preeclampsia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sflt-1-plgf-and-vegf-in-the-differential-diagnosis-between-active-sle-nephritis-during-pregnancy-and-preeclampsia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology